45 research outputs found
Genetic maps of linkage group (LG) 1 constructed using the ‘Royal Gala’בGranny Smith’ segregating population.
No full text<p>Marker names indicate the type of SNP, physical location on the ‘Golden Delicious’ genome assembly (in base pair), cluster marker, minor allelic frequency (MAF) in the 27 re-sequenced accessions, gene model, position in the predicted gene model, and NCBI dbSNP accession number (in parentheses).</p
Allerton Park as Metaphor
No full textAllerton Park Institutes are part of a long tradition, but the one in 1987
has been presented in a somewhat different way from earlier ones. There
were options on programs to attend, opportunities for considerable
interaction, a spirit of informality, and time to share problems and learn
from the problems of other participants. The setting of Allerton Park is
a metaphor for the activity. It has allowed for freedom and diversity,
humor and sociability, isolation and thought. It is a good place for a
group to gather, to get a better grip on its pride and purpose. It is
important for those of us who are administrators and leaders in librarianship
to do this periodically, and we have benefited from this
experience.Submitted by Russell Clark ([email protected]) on 2007-07-23T20:08:50Z
No. of bitstreams: 1
Sullivan143148.pdf: 349339 bytes, checksum: bed052242d22f3c4fbb36079b6c00db7 (MD5)Made available in DSpace on 2007-07-23T20:08:50Z (GMT). No. of bitstreams: 1
Sullivan143148.pdf: 349339 bytes, checksum: bed052242d22f3c4fbb36079b6c00db7 (MD5)
Previous issue date: 1987published or submitted for publicatio
San Bernardino de Siena; Cajonera
No full textIglesia de San FranciscoFondo de Recuperación Next Generation E
DataSheet_1_Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study.docx
No full textObjectiveA link has been proposed between glucose homeostasis and bone metabolism. Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate.Research Design and MethodsWe conducted a population-based nested case-control study through access to all discharge diagnoses (ICD-10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. All cases with a diagnosis of type 2 diabetes between 2008 and 2018 were matched on sex and age with 3 randomly selected controls by incidence-density sampling. Exposure was defined as ever use of alendronate and further grouped as effective and compliant use. ORs were calculated by conditional logistic regression analysis with adjustment for several confounders and test for trend for dose-response relationship.ResultsWe included 163,588 patients with type 2 diabetes and 490,764 matched control subjects with a mean age of 67 years and 55% male subjects. The odds of developing type 2 diabetes were lower among ever users of alendronate (multiple adjusted OR: 0.64 [95% CI 0.62-0.66]). A test for trend suggested a dose-response relationship between longer effective use of alendronate and lower risk of type 2 diabetes.ConclusionThese results suggest a possible protective effect of alendronate in a dose-dependent manner against development of type 2 diabetes.</p
DataSheet_1_The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.docx
No full textObjectivePatients with diabetes mellitus have an increased risk of fractures; however, the underlying mechanism is largely unknown. We aimed to investigate whether the risk of major osteoporotic fractures in diabetes patients differs between subjects initiated with alendronate and denosumab, respectively.Methods and Research DesignWe conducted a retrospective nationwide cohort study through access to all discharge diagnoses (ICD-10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. We identified all subjects with a diabetes diagnosis between 2000 and 2018 and collected data on the first new prescription of anti-osteoporotic treatment between 2011 and 2018. Exposure was defined as either alendronate or denosumab treatment initiated after diabetes diagnosis. Outcome information was collected by identification of all major osteoporotic fracture (MOF) diagnoses, i.e., hip, spine, forearm, and humerus, from exposure until 2018 or censoring by emigration or death. The risk of fracture was calculated as hazard ratios (HR) using multiply adjusted Cox proportional models with death as a competing risk.ResultsWe included 8,745 subjects initiated with either alendronate (n = 8,255) or denosumab (n = 490). The cohort consisted of subjects with a mean age of 73.62 (SD ± 9.27) years, primarily females (69%) and suffering mainly from type 2 diabetes (98.22%) with a median diabetes duration at baseline of 5.45 years (IQR 2.41–9.19). Those in the denosumab group were older (mean 75.60 [SD ± 9.72] versus 73.51 [SD ± 9.23] years), had a higher proportion of women (81% versus 68%, RR 1.18 [95% CI 1.13–1.24], and were more comorbid (mean CCI 2.68 [95% CI 2.47–2.88] versus 1.98 [95% CI 1.93–2.02]) compared to alendronate initiators. In addition, denosumab users had a higher prevalence of previous fractures (64% versus 46%, RR 1.38 [95% CI 1.28–1.48]). The adjusted HR for any MOF after treatment initiation with denosumab was 0.89 (95% CI 0.78–1.02) compared to initiation with alendronate.ConclusionThe risk of incident MOF among subjects with diabetes was similar between those initially treated with alendronate and denosumab. These findings indicate that the two treatment strategies are equally effective in preventing osteoporotic fractures in subjects with diabetes.</p
Pearson's correlation coefficient between parameters of bone turnover and calcitropic hormones of 7 subadult bears in Sweden in 2010 during hibernation in winter and the active state in the summer.
No full texta<p>p = 0.08, *Significant correlation, i.e. p<0.05.</p
What to expect and when to expect it: an fMRI study of expectancy in children with ADHD symptoms
No full textChanges in cognitive control and timing have both been implicated in ADHD. Both are involved in building and monitoring expectations about the environment, and altering behavior if those expectations are violated. In ADHD, problems with expectations about future events have high face validity, as this would be associated with behavior that is inappropriate only given a certain context, similar to symptoms of the disorder. In this fMRI study, we used a timing manipulated go/nogo task to assess brain activity related to expectations about what (cognitive control) and when (timing) events would occur. We hypothesized that problems in building expectations about the environment are a more general, trans-diagnostic characteristic of children with hyperactive, impulsive and inattentive symptoms. To address this, we included children with ASD and symptoms of ADHD, in addition to children with ADHD and typically developing children. We found between-group differences in brain activity related to expectations about when (timing), but not what events will occur (cognitive control). Specifically, we found timing-related hypo-activity that was in part unique to children with a primary diagnosis of ADHD (left pallidum) and in part shared by children with similar levels of ADHD symptoms and a primary diagnosis of ASD (left subthalamic nucleus). Moreover, we found poorer task performance related to timing, but only in children with ASD and symptoms of ADHD. Ultimately, such neurobiological changes in children with ADHD symptoms may relate to a failure to build or monitor expectations and thereby hinder the efficiency of their interaction with the environment
